News

Court of Appeal orders NICE to be more open

09-May-08

NICE warns drug appraisals could take longer after drug manufacturers win Alzheimer's legal challenge.

NICE claims drug appraisals could take longer after the Court of Appeal ruled it must be more open about the way it calculates cost-effectiveness.

Last week, Eisai, manufacturer of the Alzheimer's drug donepezil (Aricept), won its argument to be given an operational version of the economical model used by NICE when it decided the drug should not be given to patients with mild Alzheimer's disease.

NICE chief executive Andrew Dillon said: 'The ruling will increase the complexity of our drug appraisals in some cases and they may take longer as a result.

'In the meantime, and in accordance with the judges' ruling, we will provide Eisai with an executable version of the economical model used in our appraisal, so that it can comment on it,' he added.

'We will then take those comments into account.'

A 'read-only' version of NICE's economic model is available but the Court of Appeal ruled an 'executable' version including additional functions and calculations should be made available to Eisai.

NICE said the economical model is put together differently for each technology appraisal. The ruling applies to this individual case and may not be borne out in other appeals.

In June last year, a judicial review ruled in favour of just one of six grievances put forward by Eisai after NICE published guidelines stating that donepezil should only be given to patients with moderate to severe Alzheimer's disease.

rachel.liddle@haymarket.com

Comment below and tell us what you think

Comments

Only registered users may comment. Log in now or register for a free account.

Login to comment


forgotten your password?

Healthcare Republic Forums

 

Registrar

Professional development - Membership of the RCGP

Dr Sathya Naidoo explains the criteria that are required for completing iMAP. Read more

How to apply for your certificate

Applying to the RCGP for your CCT recommendation now takes three clicks, writes Fiona Erasmus. Read more

A question of capacity

Medicolegal advisor, Dr John Holden addresses some dilemmas on consent that may be faced by GPs. Read more

Show all articles

 

Latest Clinical Articles

Stable angina pectoris

Section 1 Definition and pathophysiology Read more

Endometriosis

Contributed by Mr Michael Booker, consultant obstetrician & gynaecologist, and fertility specialist ... Read more

Primary hyperparathyroidism

Contributed by Mr David Scott-Coombes, consultant endocrine surgeon at the University Hospital of Wa... Read more

Show all clinical articles

MIMS Product News

Toviaz

New drug - Toviaz

Pfizer has launched Toviaz (fesoterodine), a once-daily treatment for the symptoms of overactive bla... Read more

New drug - Tasigna

Novartis has launched Tasigna (nilotinib), a new antineoplastic agent for Philadelphia chromosome po... Read more

Ciproxin licensed for UTI in children

The licence for Ciproxin (ciprofloxacin) has been extended to include the second- and third-line tr... Read more

Jobs

 

Job of the Week